The NYBCe Genomics Laboratory combines cutting‑edge molecular methods and decades of transfusion medicine expertise to deliver the highest level of accuracy ABO testing for patients and donors. By integrating sequencing‑driven assays with our deep understanding of complex and variant ABO alleles, we provide precise genotyping that supports safer transfusion decisions, resolves serologic discrepancies, and enhances donor–recipient matching.
Our team’s scientific leadership, rigorous quality standards, and commitment to innovation make NYBCe a trusted reference center for ABO genotyping and a partner in advancing the future of immunohematology.
When Is ABO Genotyping Useful?
ABO genotyping is particularly valuable in situations where routine serology does not provide a clear or reliable result, including:
- ABO typing discrepancies, such as front and back type discordance or weak or missing antigen expression
- Weak or variant ABO phenotypes, such as suspected subgroups of A or B, or unexplained mixed-field reactivity
- Patients with recent transfusion or transplant history, which can complicate routine serologic typing
- Neonatal and prenatal testing, which can be complicated by low sample volume or passive transfer of antibodies
- Patients with hematologic malignancy, in which antigen expression may be altered due to disease or therapy
- Identification of A2 solid-organ donors, when serologic testing is inconclusive
Why Choose NYBCe Genomics Laboratory?
- Expertise in ABO variant interpretation
- Sequencing-based resolution of challenging serologic cases
- Integration with immunohematology and transfusion medicine expertise
- Support for high-complexity patient populations